A Phase 1/2 interventional study of Idelalisib in Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, sponsored by Gilead Sciences. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 1/2, and was the 2nd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 9th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2010, is one of 6 in phase 1/2, and was the 8th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies. It provides the opportunity for patients to continue treatment as long as the patient is deriving clinical benefit. Patients will be followed according to the standard of care as appropriate for their type of cancer. The dose of idelalisib will generally be the same as the dose that was administered at the end of the prior study, but may be titrated up to improve clinical response or down for toxicity. Patients will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in the opinion of the investigator.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
Drug: Idelalisib
Idelalisib tablets or capsules administered orally
Also known as: Zydelig®, GS-1101, CAL-101
Overall Response Rate
Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months) plus 30 days
Duration of Response
Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Progression-Free Survival
Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Overall Survival
Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Time to Response
Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.
Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Participants were enrolled at study sites in the United States. The first participant was screened on 22 March 2010. The last study visit occurred on 18 June 2018.
| Milestone | 101-02 | 101-07 | 101-08 | 101-10 |
|---|---|---|---|---|
| Started | 191 | 241 | 64 | 18 |
| Completed | 50 | 114 | 43 | 5 |
| Not completed | 141 | 127 | 21 | 13 |
| Milestone | 101-02 | 101-07 | 101-08 | 101-10 |
|---|---|---|---|---|
| Started | 48 | 108 | 41 | 5 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 48 | 108 | 41 | 5 |
| Withdrew: Progressive disease | 28 | 48 | 10 | 4 |
| Withdrew: Adverse event | 10 | 28 | 18 | 0 |
| Withdrew: Investigator request | 1 | 11 | 4 | 0 |
| Withdrew: Death | 3 | 8 | 1 | 0 |
| Withdrew: Sponsor discontinued study | 0 | 7 | 5 | 0 |
| Withdrew: Other (unknown reasons) | 3 | 3 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 2 | 3 | 1 |
| Withdrew: Participant request | 3 | 1 | 0 | 0 |
Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).
| percentage of participants | 101-02 (AML) | 101-02 (CLL) | 101-02 (DLBCL) | 101-02 (iNHL) | 101-02 (MCL) | 101-02 (MM) | 101-07 (CLL) | 101-07 (iNHL) | 101-07 (MCL) | 101-08 (CLL or SLL) | 101-10 (iNHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate | 0 (0 to 0) | 57.4 (43.2 to 70.8) | 11.1 (0.3 to 48.2) | 48.4 (35.8 to 61.3) | 40.0 (24.9 to 56.7) | 0 (0 to 0) | 81.7 (73.5 to 88.3) | 82.6 (72.9 to 89.9) | 57.5 (40.9 to 73.0) | 96.9 (89.2 to 99.6) | 44.4 (21.5 to 69.2) |
| percentage of participants | 101-02 | 101-07 | 101-08 | 101-10 |
|---|---|---|---|---|
| Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events | 98.4 | 98.8 | 100.0 | 94.4 |
Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.
| Months | 101-02 (AML) | 101-02 (CLL) | 101-02 (DLBCL) | 101-02 (iNHL) | 101-02 (MCL) | 101-02 (MM) | 101-07 (CLL) | 101-07 (iNHL) | 101-07 (MCL) | 101-08 (CLL or SLL) | 101-10 (iNHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | NA (NA to NA) | 21.2 (8.1 to 30.4) | NA (NA to NA) | 18.4 (10.9 to 32.4) | 2.7 (1 to 8.1) | NA (NA to NA) | 26.6 (18.5 to 44.1) | 42.9 (20.5 to 83.3) | 9.3 (5.6 to 37.5) | 63.8 (54.0 to NA) | 14.4 (6.6 to 46.3) |
Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.
| Months | 101-02 (AML) | 101-02 (CLL) | 101-02 (DLBCL) | 101-02 (iNHL) | 101-02 (MCL) | 101-02 (MM) | 101-07 (CLL) | 101-07 (iNHL) | 101-07 (MCL) | 101-08 (CLL or SLL) | 101-10 (iNHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival | 0.9 (0.4 to 1) | 15.8 (5.6 to 39.6) | 1.5 (0.3 to 4.1) | 7.6 (3.7 to 17.7) | 3.7 (2.7 to 8.2) | 1 (0.9 to 1.8) | 26.1 (19.0 to 36.8) | 32.8 (22.0 to 81.3) | 11.1 (3.4 to 12.9) | 65.6 (55.8 to NA) | 10.2 (2.8 to 19.1) |
Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.
| Months | 101-02 (AML) | 101-02 (CLL) | 101-02 (DLBCL) | 101-02 (iNHL) | 101-02 (MCL) | 101-02 (MM) | 101-07 (CLL) | 101-07 (iNHL) | 101-07 (MCL) | 101-08 (CLL or SLL) | 101-10 (iNHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival | NA (NA to NA) | NA (39.7 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 5.2 (1.2 to 5.2) | NA (50.2 to NA) | NA (NA to NA) | NA (NA to NA) | NA (66.3 to NA) | NA (10.3 to NA) |
Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.
| Months | 101-02 (AML) | 101-02 (CLL) | 101-02 (DLBCL) | 101-02 (iNHL) | 101-02 (MCL) | 101-02 (MM) | 101-07 (CLL) | 101-07 (iNHL) | 101-07 (MCL) | 101-08 (CLL or SLL) | 101-10 (iNHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Response | — | 1.9 (1.0 to 7.5) | 4.0 (4.0 to 4.0) | 1.3 (1.0 to 3.7) | 1.1 (1.0 to 1.9) | — | 1.9 (1.9 to 1.9) | 1.9 (1.9 to 3.0) | 1.9 (1.9 to 2.0) | 1.9 (1.9 to 1.9) | 2.7 (2.6 to 3.1) |
Collected over First dose date in parent study to end of study 101-99 (maximum: up to 91.2 months) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 101-02 | 25/191 (13.1%) | 100/191 (52.4%) | 183/191 (95.8%) |
| 101-07 | 36/241 (14.9%) | 165/241 (68.5%) | 236/241 (97.9%) |
| 101-08 | 7/45 (15.6%) | 45/64 (70.3%) | 63/64 (98.4%) |
| 101-10 | 2/6 (33.3%) | 6/18 (33.3%) | 16/18 (88.9%) |
| Event | 101-02 | 101-07 | 101-08 | 101-10 |
|---|---|---|---|---|
| ColitisGastrointestinal disorders | 8/191 | 14/241 | 13/64 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 9/191 | 14/241 | 13/64 | 0/18 |
| PneumoniaInfections and infestations | 30/191 | 40/241 | 12/64 | 1/18 |
| PyrexiaGeneral disorders | 6/191 | 31/241 | 3/64 | 0/18 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/191 | 4/241 | 0/64 | 2/18 |
| Renal failureRenal and urinary disorders | 3/191 | 0/241 | 0/64 | 2/18 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/191 | 23/241 | 3/64 | 0/18 |
| SepsisInfections and infestations | 4/191 | 14/241 | 1/64 | 1/18 |
| Atrial fibrillationCardiac disorders | 0/191 | 3/241 | 0/64 | 1/18 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/191 | 2/241 | 0/64 | 1/18 |
| Event | 101-02 | 101-07 | 101-08 | 101-10 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 58/191 | 106/241 | 36/64 | 8/18 |
| FatigueGeneral disorders | 63/191 | 85/241 | 21/64 | 8/18 |
| Alanine aminotransferase increasedInvestigations | 33/191 | 52/241 | 18/64 | 8/18 |
| Aspartate aminotransferase increasedInvestigations | 35/191 | 47/241 | 18/64 | 8/18 |
| NeutropeniaBlood and lymphatic system disorders | 31/191 | 102/241 | 5/64 | 3/18 |
| PyrexiaGeneral disorders | 49/191 | 92/241 | 26/64 | 5/18 |
| NauseaGastrointestinal disorders | 44/191 | 81/241 | 24/64 | 7/18 |
| RashSkin and subcutaneous tissue disorders | 39/191 | 65/241 | 24/64 | 5/18 |
| ChillsGeneral disorders | 31/191 | 40/241 | 23/64 | 2/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/191 | 81/241 | 21/64 | 4/18 |
Data presented includes baseline characteristic data for all participants who received any dose of idelalisib in the parent studies, excluding Cohort 2 participants from Study 101-08 who were not eligible to enroll into Study 101-99.
| Age, Customized(Participants) | 101-02 | 101-07 | 101-08 | 101-10 | Total |
|---|---|---|---|---|---|
| < 65 years | 86 | 116 | 0 | 13 | 215 |
| ≥ 65 years | 105 | 125 | 64 | 5 | 299 |
| Sex: Female, Male(Participants) | 101-02 | 101-07 | 101-08 | 101-10 | Total |
|---|---|---|---|---|---|
| Female | 52 | 76 | 24 | 8 | 160 |
| Male | 139 | 165 | 40 | 10 | 354 |
| Ethnicity (NIH/OMB)(Participants) | 101-02 | 101-07 | 101-08 | 101-10 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 0 | 1 | 7 |
| Not Hispanic or Latino | 167 | 234 | 64 | 17 | 482 |
| Unknown or Not Reported | 22 | 3 | 0 | 0 | 25 |
| Race/Ethnicity, Customized(Participants) | 101-02 | 101-07 | 101-08 | 101-10 | Total |
|---|---|---|---|---|---|
| Race — White | 160 | 209 | 61 | 12 | 442 |
| Race — Black or African American | 6 | 9 | 1 | 5 | 21 |
| Race — Asian | 1 | 11 | 1 | 1 | 14 |
| Race — Other | 2 | 1 | 1 | 0 | 4 |
| Race — Not Reported | 22 | 11 | 0 | 0 | 33 |
| Diagnosis Status(Participants) | 101-02 | 101-07 | 101-08 | 101-10 | Total |
|---|---|---|---|---|---|
| Chronic lymphocytic leukemia (CLL) | 54 | 115 | 59 | 0 | 228 |
| Indolent non-Hodgkin lymphoma (iNHL) | 64 | 86 | 5 | 17 | 172 |
| Mantle cell lymphoma (MCL) | 40 | 40 | 0 | 0 | 80 |
| Diffuse large B-cell lymphoma (DLBCL) | 9 | 0 | 0 | 0 | 9 |
| Acute myeloid leukemia (AML) | 12 | 0 | 0 | 0 | 12 |
| Multiple myeloma (MM) | 12 | 0 | 0 | 0 | 12 |
| Missing | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Mar 2010 to primary completion in Jun 2018, 98 months.
Results were first posted in Aug 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →